2022 ESC速递:心力衰竭相关临床研究解读  

2022 ESC express:Interpretation of new clinical trials on heart failure

作　　者：程敏[1] 廖玉华[1] 袁璟[1] CHENG Min;LIAO Yuhua;YUAN Jing(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022

出　　处：《临床心血管病杂志》2022年第10期774-776,共3页Journal of Clinical Cardiology

摘　　要：2022年8月,在西班牙巴塞罗那召开的ESC大会发布了DELIVER研究、PERSPECTIVE研究及ADVOR研究等心力衰竭重磅研究结果,给心力衰竭的治疗带来了新的循证医学证据。In August 2022, the ESC Conference held in Barcelona, Spain, released the latest results of DELIVER, PERSPECTIVE, ADVOR clinical trial about heart failure, bringing new concept of evidence-based medical treatment to the heart failure.

关 键 词：ESC速递 心力衰竭 DELIVER研究 

分 类 号：R541.6[医药卫生—心血管疾病]